1887

Abstract

Resistance to antibiotics, especially clarithromycin, is the major cause of the failure to eradicate . There are few studies in children concerning fluoroquinolone activity against . Primary resistance to antibiotics including fluoroquinolones was studied in 55 strains isolated from Japanese children. DNA sequences of the gene in fluoroquinolone-resistant strains were determined. Twelve strains (21.8 %) were resistant to clarithromycin and three (5.5 %) were resistant to both levofloxacin and ciprofloxacin. Out of 12 clarithromycin-resistant strains, 11 (91.7 %) were susceptible to levofloxacin and ciprofloxacin. Sequence analysis in three fluoroquinolone-resistant strains showed point mutations of the gene at G271A, G271T and A272G, indicating mutations of the codon Asp91 in the fluoroquinolone-resistance-determining region of the DNA gyrase. The results suggest that fluoroquinolones should be considered as an option for second- or third-line eradication therapy in children.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.45642-0
2004-10-01
2020-10-22
Loading full text...

Full text loading...

/deliver/fulltext/jmm/53/10/JM531011.html?itemId=/content/journal/jmm/10.1099/jmm.0.45642-0&mimeType=html&fmt=ahah

References

  1. Adamek R. J., Suerbaum S., Pfaffenbach B., Opferkuch W. 1998; Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole and amoxicillin: influence on treatment outcome. Am J Gastroenterol 93:386–389
    [Google Scholar]
  2. Boyanova L., Stancheva I., Spassova Z., Katzarov N., Mitov I., Koumanova R. 2000; Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. J Med Microbiol 49:415–418
    [Google Scholar]
  3. Cabrita J., Oleastro M., Matos R. & 7 other authors; 2000; Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 46:1029–1031 [CrossRef]
    [Google Scholar]
  4. Croom K. F., Goa K. L. 2003; Levofloxacin : a review of its use in the treatment of bacterial infections in the United States. Drugs 63:2769–2802 [CrossRef]
    [Google Scholar]
  5. European Helicobacter pylori Study Group (1997; Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus report. Gut 41:8–13 [CrossRef]
    [Google Scholar]
  6. Falsafi T., Mobasheri F., Nariman F., Najafi M. 2004; Susceptibilities to different antibiotics of Helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran. J Clin Microbiol 42:387–389 [CrossRef]
    [Google Scholar]
  7. Fujimura S., Kato S., Kawamura T., Watanabe A. 2002; In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults. J Antimicrob Chemother 49:541–543 [CrossRef]
    [Google Scholar]
  8. Gendrel D., Chalumeau M., Moulin F., Raymond J. 2003; Fluoroquinolones in pediatrics: a risk for the patient or for the community?. Lancet Infect Dis 3:537–546 [CrossRef]
    [Google Scholar]
  9. Glupczynski Y., Megraud F., Lopez-Brea M., Andersen L. P. 2001; European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori . Eur J Clin Microbiol Infect Dis 20:820–823 [CrossRef]
    [Google Scholar]
  10. Heep M., Kist M., Strobel S., Beck D., Lehn N. 2000; Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 19:538–541 [CrossRef]
    [Google Scholar]
  11. Kato M., Yamaoka Y., Kim J. J. & 7 other authors; 2000; Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 44:2214–2216 [CrossRef]
    [Google Scholar]
  12. Kato S., Fujimura S., Udagawa H., Shimizu T., Maisawa S., Ozawa K., Iinuma K. 2002; Antibiotic resistance of Helicobacter pylori strains in Japanese children. J Clin Microbiol 40:649–653 [CrossRef]
    [Google Scholar]
  13. Lind T., Megraud F., Unge P. & 9 other authors; 1999; The MACH 2 study: role of omeprazole in eradication of Helicobacter pylori with 1 week triple therapies. Gastroenterology 116:248–253 [CrossRef]
    [Google Scholar]
  14. Megraud F., Lehn N., Lind T. & 7 other authors; 1999; Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 43:2747–2752
    [Google Scholar]
  15. Moore R. A., Beckthold B., Wong S., Kureishi A., Bryan L. 1995; Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori . Antimicrob Agents Chemother 39:107–111 [CrossRef]
    [Google Scholar]
  16. Murakami K., Sato R., Okimoto T. & 7 other authors; 2002; Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 16:1933–1938 [CrossRef]
    [Google Scholar]
  17. National Committee for Health; 1994; Consensus conference: Helicobacter pylori in peptic ulcer disease. JAMA (J Am Med Assoc) 272:65–69 [CrossRef]
    [Google Scholar]
  18. Nista E. C., Candelli M., Cremonini F. & 10 other authors; 2003; Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. Aliment Pharmacol Ther 18:627–633 [CrossRef]
    [Google Scholar]
  19. Takada S., Kato M., Takayama S. 1994; Comparison of lesions induced by intra-articular injections of quinolones and compounds damaging cartilage components in rat femoral condyles. J Toxicol Environ Health 42:73–88 [CrossRef]
    [Google Scholar]
  20. Wang G., Wilson T. J. M., Jiang Q., Taylor D. E. 2001; Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori . Antimicrob Agents Chemother 45:727–733 [CrossRef]
    [Google Scholar]
  21. Watanabe Y., Aoyama N., Shirasaki D. & 8 other authors; 2003; Levofloxacin based triple therapy as a second-line treatment after failure of Helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 35:711–715 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.45642-0
Loading
/content/journal/jmm/10.1099/jmm.0.45642-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error